Component
Serum N-glycan galactosylation
Serum N-glycan galactosylation. Experimental scope belongs to each linked claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Oral galactose improved transferrin glycoform patterns and reduced hypogalactosylated serum N-glycans in the two TMEM165-CDG patients.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- cross_nutrient
- Human TMEM165 deficiency (underlying_defect)
- evidence_span
- {"source_cache": "artifacts/manganese-clinical-sources/tmem165patients.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "3899c8a8d58b702858b7e1e74723d46a9825f4d7846b969ccf33db688fa16eac", "start_char": 0, "end_char": 2039, "text_sha256": "3899c8a8d58b702858b7e1e74723d46a9825f4d7846b969ccf33db688fa16eac", "text_characters": 2039}
- experimental_model
- Two unrelated patients with TMEM165-CDG
- exposure
- Oral D-galactose; indexed abstract reports 1 g/kg/day in individuals homozygous for c.792+182G>A.
- limitations
- Primary abstract used for these claims; this nominal amount is not a reconstruction of the full titration schedule. Cell manganese-rescue experiments in the same paper must not be recast as manganese treatment of the patients.
- nutrient_topic
- Manganese research collection; topical membership is not evidence of a direct dietary effect. · Manganese
- organism
- Homo sapiens
- plain_language
- Galactose improved selected blood sugar-chain markers despite the genetic defect.
- primary_references
- [mn-clin-tmem165patients] Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects. (2017). https://pubmed.ncbi.nlm.nih.gov/28323990/ DOI: 10.1210/jc.2016-3443
- tissue_or_cell_type
- Serum glycosylation
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
Manganese: enzyme cofactors, glycosylation, transport and nutrient interactions (2026-09-17) · lines 1244–1256
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two unrelated patients with TMEM165-CDG · source_derived_draft · unverified_draft
### mn-clin-tmem165-gal-patients Oral galactose improved transferrin glycoform patterns and reduced hypogalactosylated serum N-glycans in the two TMEM165-CDG patients. Condition category: machinery_impairment nutrient_topic: Manganese research collection; topical membership is not evidence of a direct dietary effect. plain_language: Galactose improved selected blood sugar-chain markers despite the genetic defect. organism: Homo sapiens tissue_or_cell_type: Serum glycosylation experimental_model: Two unrelated patients with TMEM165-CDG limitations: Primary abstract used for these claims; this nominal amount is not a reconstruction of the full titration schedule. Cell manganese-rescue experiments in the same paper must not be recast as manganese treatment of the patients. exposure: Oral D-galactose; indexed abstract reports 1 g/kg/day in individuals homozygous for c.792+182G>A. cross_nutrient: Human TMEM165 deficiency (underlying_defect) evidence_span: {"source_cache": "artifacts/manganese-clinical-sources/tmem165patients.abstract.txt", "locator": "Indexed primary abstract", "file_sha256": "3899c8a8d58b702858b7e1e74723d46a9825f4d7846b969ccf33db688fa16eac", "start_char": 0, "end_char": 2039, "text_sha256": "3899c8a8d58b702858b7e1e74723d46a9825f4d7846b969ccf33db688fa16eac", "text_characters": 2039} [mn-clin-tmem165patients] Galactose Supplementation in Patients With TMEM165-CDG Rescues the Glycosylation Defects. (2017). https://pubmed.ncbi.nlm.nih.gov/28323990/ DOI: 10.1210/jc.2016-3443
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.